Isonicid

Isoniazid, the active ingredient in Isonicid, is an antitubercular agent presented as an oral tablet for oral administration. It is used to treat active tuberculosis disease in adults and children, typically as part of a multidrug regimen to prevent resistance and achieve bacterial eradication. The drug is approved in the European Union and is supplied in compliance with GMP standards. Isoniazid works by targeting the mycobacterial cell wall synthesis, making it a cornerstone of first‑line TB therapy.

GNH USA supplies Isonicid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isoniazid is an antitubercular agent used in the treatment of Mycobacterium tuberculosis infection.

- Active tuberculosis: used as part of initial phase therapy to kill replicating bacilli and reduce disease burden. - Latent tuberculosis infection: administered alone or with rifampin to prevent progression to active disease. - Tuberculosis prophylaxis in high‑risk contacts: reduces the risk of developing active TB after exposure. - TB prevention in HIV‑positive individuals: lowers the incidence of active tuberculosis in immunocompromised patients.

Isoniazid may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Loss of appetite: reduced desire to eat. - Peripheral neuropathy: tingling or numbness in extremities. - Rash: skin irritation or mild eruption. - Elevated liver enzymes: mild, often asymptomatic.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury, jaundice, or hepatitis. - Severe allergic reactions (anaphylaxis): difficulty breathing, swelling, or hives. - Sideroblastic anemia: impaired red blood cell production. - Stevens‑Johnson syndrome: severe skin blistering. - Drug‑induced lupus: joint pain and fever.

Before prescribing Isonicid, clinicians should consider several safety measures.

- Liver function monitoring: assess baseline and periodic LFTs due to risk of hepatotoxicity. - Alcohol consumption: avoid or limit as it increases liver toxicity. - Vitamin B6 supplementation: consider pyridoxine to prevent peripheral neuropathy. - Pregnancy: use only if benefit outweighs risk; data are limited. - Renal impairment: dose adjustment may be needed in severe renal dysfunction. - Store at room temperature: keep in original container, protect from moisture and heat.

Isoniazid can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Rifampin: induces hepatic enzymes, lowering isoniazid plasma levels. - Phenytoin: increases metabolism, reducing therapeutic effect. - Alcohol: additive hepatotoxic risk.

Moderate Interactions (Monitor Closely): - Acetaminophen: concurrent use may raise liver enzyme levels. - Nevirapine: monitor liver function during combined therapy. - Macrolide antibiotics (e.g., erythromycin): may increase isoniazid concentrations.